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Abstract: Digital ulcers (DUs) represent a severe and 
common complication occurring in patients affected 
by Systemic Sclerosis (SSc), with a consistent 
impact on the quality of life and often resulting in 
longer hospitalization than unaffected patients. 
Conventional treatment of SSc ulcers consists of 
both topical and systemic (oral or intravenous) 
pharmacological therapies. Several surgical options 
are also available, but there is overall a lack  of 
official guidelines or recommendations. 
The aim of this study was to evaluate the efficacy of 
a novel local therapy based on  polyurethane foam 
dressings, namely the Highly Hydrophilic 
Polyurethane Foam (HPF), in addition to the 
conventional pharmacological treatment,  in a cohort 
of 41 SSc patients with at least one active ulcer. 
Our results showed that the addition of HPF to the 
conventional treatment based on systemic drugs 
induced i) a significant reduction in the number of 
active DUs (p=0.0034); ii) a significant reduction of 
the mean duration of ulcer-related hospitalization as 
compared with standard therapy (p=0.0001); iii) a 
significant improvement of patients’ Quality of Life, 
as evaluated through the Scleroderma Health 
Assessment Questionnaire (SHAQ) (p=0.00011). 
Therefore, in our experience, the combined 
management of DUs can improve both the onset of 
new DUs and DU’s healing thus leading to a better 
outcome. 
I INTRODUCTION 
Systemic sclerosis (SSc) is a chronic multisystemic 
disease characterized by immune deregulation with 
specific autoantibodies, vascular dysfunction and 
increased fibroblast activity resulting in diffuse fibrosis 
[1].  
Digital ulcers (DUs) represent a very common and serious 
clinical manifestation of the vascular damage observed in 
SSc; they can indeed be considered as an end-organ 
damage resulting from progressive vasculopathy and a 
biomarker of disease activity and organ impairment [2]. 
At least one DU can occur approximately in half (44-60%) 
of affected patients [3].  
These lesions severely limit patients’ everyday life, 
impacting over Quality of Life (QoL) and morbidity [4]. 
Ulcers can also have serious complications, such as 
infections and tissue loss, gangrene, osteomyelitis, 
potentially leading to amputation [4]. SSc patients with 
DUs often experience anxiety and a significant disability, 
representing a consistent economic burden due to a higher 
hospitalisation rate and the need of advanced therapies [5, 
6]. 
DUs are commonly defined as areas of denuded tissue 
affecting the dermal and epidermal skin layers, usually 
involving fingertips; they can be multiple, recurrent, 
painful and difficult to heal [7,8].  Although authors use a 
variety of indicators to assess DU, such as size, number, 
location, loss of function, pain, infection and evolution to 
gangrene and time to healing, these items have been not 
yet fully validated. To define precisely what is an SSc 
ulcer is still an unmet need, despite DU prevention and 
healing have been primary endpoints in several clinical 
trials [9,10]. Recently Suliman et al., taking advantage 
from the World Scleroderma Foundation (WSF), 
developed a preliminary consensus based definition of 
SSc-skin ulcers [11].  
In 2009 recommendations on management of digital 
vascular disease were published from EULAR experts 
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[12]. The medical management of patients presenting this 
condition is often left to tertiary referral centers and is 
primarily conservative, involving both topic and systemic 
(oral or intravenous) therapies as first-line vasodilators 
(i.e. calcium channel blockers), Phosphodiesterase 5 
inhibitors (PDE5i), Prostaglandin E1 (PGE1)/prostacyclin, 
Endothelin Receptor Antagonist (ERA), antiplatelet and 
antithrombin agents [13].   
Many surgical options are also available, such as 
botulinum injections and digital sympathectomy [14].  
However, clinicians are still lacking guidelines on the best 
management of DUs in SSc patients. In 2015, the UK 
Scleroderma Study Group developed three clinical 
algorithms intended to provide the best consensus 
recommendations for the management of SSc-specific 
complications, including digital vasculopathy [15].  
The guidelines of the European Society for Vascular 
Medicine and an update of the EULAR recommendations 
for the management of Raynaud’s phenomenon (RP) have 
been recently published, however the evidence for their 
efficacy in the treatment of both primary and secondary 
RP is weak or moderate  [16,17]. 
Highly Hydrophilic Polyurethane Foam (HPF)  dressing is 
commonly used in clinical practice and its efficacy has 
been widely described in the treatment of diabetic foot 
ulcers [18] and pressure ulcers [19]. Polyurethane foam 
dressings have been used worldwide to accelerate wound 
healing, however no clinical studies demonstrate the 
efficacy of this novel foam dressing on scleroderma 
ulcers.  
Aim of this study was to evaluate the effects of 
polyurethane foam dressings as an “add-on” therapy for 
SSc patients affected by DUs, on both number of ulcers 
and QoL. 
 
II. METHODS 
The study is designed as a retrospective cohort study in 
which data are evaluated from the medical records of 41 
SSc patients ≥18 year-old, admitted to the Department of 
Translational Medical Sciences - Autoimmune Diseases 
Unit of the University of Naples Federico II, classified 
according to the ACR/ EULAR criteria [20] and followed 
up during the period from January 2015 to January 2017. 
The main inclusion criterion was the presence of at least 
one active DU. Active DUs were determined by the 
physician and defined as a painful area of at least 2 mm in 
diameter characterized by visible depth and loss of dermis. 
DUs were localized in the palmar or dorsal surface of a 
finger, or sited next to an inter-phalangeal joint. No DU 
was associated with calcinosis.  Patients with DUs not due 
to systemic sclerosis, and those affected by disorders that 
could represent confounding factors in assessing hand 
functionality (amputations, arthritis, other connective 
tissue diseases), were excluded from the study. Patients 
with diabetes, cancer, and heart or kidney failure were 
also excluded.  
41 patients were consecutively enrolled and observed for 
24 months. All patients underwent conventional therapy 
based on vasodilators (i.e. calcium channel blockers), 
PDE5i, PGE1/prostacyclin, ERA, antiplatelet and 
antithrombin agents (Table 1) for 12 months; polyurethane 
foam dressings treatment was then added for an additional 
12 months. Since digital ulcers may be significantly 
painful, the use of Paracetamol as a painkiller, at the dose 
of one or two 500 mg tablets up to 4 times in 24 hours, 
was allowed. Medication with polyurethane foam dressing 
was changed daily after cleansing with a 0.9% saline 
solution. No other debridement of the ulcers was 
effectuated. All patients received a monthly routine check 
up.  
The study was conducted in accordance with the 
principles of the Declaration of Helsinki and good clinical 
practice guidelines of the International Conference of 
Harmonization (ICH GCP); all patients gave their written 
informed consent and the study was approved by the  
 
Table 1  
Demographics and clinical parameters of the study population. 
Data are expressed as percentages.  
List of abbreviations: SSc, Systemic Sclerosis; ACA, anti-centromere 
antibodies;  anti-Scl70 antibodies, anti-DNA Topoisomerase I, NVC, 
Nailfold video-capillaroscopy; CCB, Calcium channel blockers; PDE5i, 
Phosphodiesterase 5 inhibitors; PGE1, prostaglandin E; ERA, endothelin 
receptor antagonist. 
Clinical features of SSc patients 
Women 
Men 
Age, mean ±SD years 
Disease duration, mean ±SD years 
Local SSc  (lSSc) 
Diffuse SSC  (dcSSc) 
Puffy fingers  
DLCO <80% 
Dyspnoea 
ACA positive 
Anti-Scl 70 positive 
NVC early pattern 
NVC active pattern 
NVC late pattern 
CCB 
PDE5i 
PGE1/prostacyclin 
ERA 
Antiplatelet agents 
35 (85%) 
6 (15%) 
51,9 (± 14.5)  
15,6 (± 11.5)  
19 (46%) 
22 (54%) 
31 (76%) 
12 (28%) 
14 (34%) 
20 (49%) 
21 (51%) 
8 (19%) 
10 (24%) 
23 (57%) 
39 (95%) 
3 (7%) 
38 (93%) 
28 (68%) 
37 (90%) 
 
ethical committee of the University of Naples Federico II 
(Protocol No. 348/2018, approved 14/03/18).  
The overall physical disability was assessed by the Health 
Assessment Questionnaire for systemic sclerosis (SHAQ) 
[21].  
Statistical analysis was performed by student T-test. 
Continuous variables are expressed as mean ± standard 
deviation; categorical variables are expressed as 
frequencies or percentages and differences were 
considered significant when p <0.05. 
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III. RESULTS 
The characteristics of the study population are listed in 
Table 1: the majority of patients were female (85%) with 
the disease diagnosed more than a decade prior to the 
study (mean 15.6 yrs). The most common SSc subset was 
the diffuse one (54% vs 46%), with frequent positivity for 
Scl-70 topoisomerase I antibodies. Both groups 
experienced at least one active DUs (Fig. 1), and there 
was no significant difference between them concerning 
the clinical manifestations. Capillaroscopy was routinely 
performed: at T0 more than half the patients already 
showed a “late” pattern (Fig. 2). All patients underwent a 
combination therapy with Iloprost and vasodilators 
(100%), 37 patients (90%) were under antiplatelet agents 
and 68% of them also assumed ERA.  
The HPF “add-on” treatment led to a significant reduction 
of the number of active DUs (mean 1,57 vs 1,09; p 
<0,0001), as shown in Figure 3A. 
Also, the mean duration of ulcer-related hospitalization 
was significantly reduced following the addition of the 
polyurethane foam dressings (mean 9,07 days vs 7,87; p 
<0,0001, Figure 3B). 
 
 
 
 
 Fig. 1. Digital ulcers in a male patient at T0 and after 4 weeks. 
Moreover, while 2 patients under “traditional” therapy 
underwent amputations of phalanges before the 
introduction of the HPF treatment, no new amputations 
were registered in the year following the introduction of 
the HPF therapy.  
Finally, Fig. 3 shows significantly improved scores (1,56 
vs 1,09; p <0,0001) in SHAQ in the 12 months following 
the introduction of the HPF treatment (white columns) in 
comparison with the conventional therapies alone (black 
columns).  
 
IV. DISCUSSION 
DUs are a very common visible expression of the 
progressive vascular damage that occurs in SSc usually  
requiring complex  poly-therapy mainly based on systemic 
drugs and surgical approaches. Ulcers can also lead to 
amputation and debridement plays a crucial role to 
prevent further complications.  
 
Fig. 2. Nailfold exam at T0. It is possible to observe a late scleroderma 
pattern characterized by a severe capillary architecture disorganization 
with loss of capillaries, very few giant capillaries, absence of 
haemorrhages, and large avascular areas.  
Debridement can be achieved through various methods 
(surgical, enzymatic, autolytic, mechanic, or biological) 
mostly depending on the extension of necrotic areas and 
on the patient’s compliance.  
Although many official protocols share DUs 
pharmacological treatment [22], there is limited evidence 
to guide clinicians in the management of SSc-related 
digital vasculopathy. The UK Scleroderma Study Group 
produced recommendations for the management of SSc-
specific complications, including digital vasculopathy 
[15]. 
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Scrupulous consideration must be given to wound care of 
digital ulcers, especially in relation to the severity and the 
physical condition (e.g. wet or dry) of the ulcer. 
Moreover, while there is agreement about acute  
 
Fig. 3. Number of active ulcers, hospitalization rates (expressed as days 
of hospital stay) and Scleroderma Heatlh Assessment Questionnaires 
(SHAQ), as indices of quality of life, are represented before and after the 
introduction of HPF as an add-on therapy. Each parameter results 
significantly reduced when patients undergo combined therapy.  
* p<0.05. List of abbreviations: DUs, Digital Ulcers; HPF, highly 
hydrophilic polyurethane foam. Data is expressed as mean +- standard 
deviation. 
 
procedures [23], no indication is available on chronic 
maintenance. 
Overall therapy is actually based on the everyday practice 
and can differ from one centre to another. 
Polyurethane belongs to the group of hydro-active 
dressings. They are used in exuding wounds as they 
guarantee the removal of exceeding exudates, thus 
preventing the creation of a too dry environment. 
Polyurethane is a highly absorbent polymer that traps 
fluids, thus maintaining a damp setting. A good balance 
between moisturizing the wound site and absorbing 
exudate is essential for optimal wound healing because 
cell migration is encouraged, leading to re-
epithelialization. 
Like semi-permeable dressings, it protects perilesional 
skin from maceration thus preventing wound enlargement 
and pain increase. At the same time, it acts like a physical 
barrier, limiting bacterial colonization from the 
environment.  
Polyurethane dressings are easy to handle especially when 
used on joints and fingers since they are ductile enough to 
expand and contract without blocking the wounded part. 
They also help to avoid micro-traumas during daily 
activities. Moreover, they are well tolerated by patients as 
they are "comfortable". 
In our experience, polyurethane foam dressings treatment 
proved successful in DUs healing in SSc patients. The 
close observation of exudates from wounds and the 
selection of appropriate dressing are crucial, considering 
the general cost and the wound management properties 
offered by each dressing type. We chose this kind of 
dressing first of all because it is not particularly expensive 
as compared to other similar devices currently used for the 
treatment of ulcers. Moreover, since SSc patients often 
have to deal with chronic ulcers, advanced polyurethane 
foam dressings can be easily handled at home, as this 
medication requires minimum management, thus 
consistently reducing the risk of infection and ensuing 
complications. It should also be taken into account that all 
SSc patients may undergo immunological therapy with 
immunosuppressive drugs because of multiorgan 
involvement. These drugs, lowering the body immune 
response, make it easier for infections to occur and to 
cause severe complication, such as amputation.  
DUs, as one of the main complications, represent a 
consistent burden not only to SSc patient but also to 
society: besides affecting patient’s working ability to cope 
with common daily activities, they also have a consistent 
economic cost since DUs treatment requires frequent 
hospitalization and highly expensive therapies [24]. 
As a matter of fact, the introduction of polyurethane foam 
dressings considerably reduced the average length of 
hospitalization as observed over one-year follow-up. A 
reduced need for hospital admissions emerged as well, 
since the simple  polyurethane foam dressing application 
can actually be performed at home, allowing  patients to 
be dismissed earlier, consequently reducing both direct 
and indirect DU-related healthcare costs. 
As reported, a change in digital ulcers status was 
accompanied by an improvement in the QoL patient 
reported outcome [21]; indeed,  we observed a significant 
change in the SHAQ score with a better global health 
status.  
Scleroderma-related DUs are a serious cause of morbidity. 
The search for well-tolerated, inexpensive therapeutic 
options for the treatment of this complication is still an 
unmet need.  
In order to assess and confirm the efficacy of  HFP as an 
add-on treatment in patients affected by DUs in the 
context of SSc, a larger sample of patients may be 
required. What emerges from this study is that the 
combined management of DUs, as compared to  
pharmacological therapy alone, can favour their healing. 
Moreover, the combined therapy determines not only a 
decrease in the number of DUs complications, but also a  
reduced hospitalization rate and an improvement of the 
quality of life, thus leading to a better outcome.  
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